A Phase I Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer
Latest Information Update: 30 May 2025
At a glance
- Drugs JNJ 89402638 (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions
- Sponsors Janssen Research & Development
Most Recent Events
- 23 May 2025 Planned number of patients changed from 120 to 170.
- 04 Nov 2024 New trial record